LW231

Phase 1Small molecule

SShanghai Longwood Biopharmaceuticals Co., Ltd.

LW231 is one of 73 small molecule programs targeting Chronic Hepatitis. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic HepatitisActive, not recruiting

Chronic Hepatitis B Virus InfectionActive, not recruiting

Chronic HepatitisPhase 1/Phase 2

Active, not recruiting

Chronic Hepatitis B Virus InfectionPhase 1

Active, not recruiting

Competition

Competitive Landscape

624 competitors in Chronic Hepatitis

#DrugCompanyPhaseTrials

Sovaldi

Gilead

Preclinical

34 2

Virazole

CConrado Roberto Hoffmann Filho

Preclinical

199 3

Incivek

Vertex Pharmaceuticals

Preclinical

10 4

Intron a

Sanofi

Preclinical

7 5

Roferon-a

Roche

Preclinical

3 6

Medrol

Pfizer

Preclinical

1 7

Dasabuvir

AbbVie

Preclinical

7 8

SOF/VEL

Gilead

Preclinical

4 9

Keyhole-Limpet Hemocyanin

Bristol-Myers Squibb

Preclinical

1 10

Pegintron

Merck & Co.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1/2Recruiting

Chronic Hepatitis

NCT07179575

Clinical

Trials by Indication[1]

Chronic Hepatitis1 trial

Study of LW231 in Participants With Chronic Hepatitis B

Recruiting·SShanghai Longwood Biopharmaceuticals Co., Ltd.·Phase 1/2·NCT07179575·270 enrolled

Chronic Hepatitis B Virus Infection1 trial

A Study of LW231 to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Volunteers and Participants With Chronic Hepatitis B Virus Infection

Completed·SShanghai Longwood Biopharmaceuticals Co., Ltd.·Phase 1·NCT06311734·119 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for LW231. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — LW231 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for LW231. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai Longwood Biopharmaceuticals Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: SShanghai Longwood Biopharmaceuticals Co., Ltd.

LW231

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Chronic Hepatitis1 trial

Chronic Hepatitis B Virus Infection1 trial

References

Drug Info

Quick Facts

Related News